Sativex - Revision history

Lazy at 08:19, 18 January 2025

2025-01-18T08:19:16Z

← Older revision		Revision as of 01:19, 18 January 2025
Line 13:		Line 13:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.		\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.
	}}		\|overview=Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:28:23Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:28, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.		\|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
	\|~~category~~=Investigational Drugs		\|treatment_category=Investigational Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.		\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.
	}}		}}

Lazy at 16:54, 27 March 2024

2024-03-27T16:54:17Z

← Older revision		Revision as of 09:54, 27 March 2024
Line 11:		Line 11:
	\|category=Investigational Drugs		\|category=Investigational Drugs
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Sativex (Nabiximols) |FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis |used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management |clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma |common_side_effects=Fatigue, dizziness, nausea, mouth irritation |OS_with=The 2021 trial reported an increase in..."

2024-03-21T12:14:08Z

Created page with "{{TreatmentInfo |drug_name=Sativex (Nabiximols) |FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis |used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management |clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma |common_side_effects=Fatigue, dizziness, nausea, mouth irritation |OS_with=The 2021 trial reported an increase in..."

New page

{{TreatmentInfo
|drug_name=Sativex (Nabiximols)
|FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
|used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
|clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma
|common_side_effects=Fatigue, dizziness, nausea, mouth irritation
|OS_with=The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
|PFS_with=Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
|usefulness_rating=4
|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
|category=Investigational Drugs
|links=
}}